Loading…
BioCardia, Inc. is projected to rise to $1.01 by 2027, a +12% move from its current price of $0.9003. BCDA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $0.8715 | $0.9009 | $0.9314 | +0.07% |
| May 30 | $0.8601 | $0.9016 | $0.945 | +0.14% |
| May 31 | $0.8517 | $0.9022 | $0.9557 | +0.21% |
| Jun 1 | $0.8447 | $0.9028 | $0.9649 | +0.28% |
| Jun 2 | $0.8387 | $0.9035 | $0.9732 | +0.35% |
| Jun 3 | $0.8334 | $0.9041 | $0.9808 | +0.42% |
| Jun 4 | $0.8285 | $0.9047 | $0.988 | +0.49% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.8285 | $0.9047 | $0.988 | +0.49% |
| Week 2 | $0.8028 | $0.9092 | $1.03 | +0.99% |
| Week 3 | $0.7845 | $0.9137 | $1.06 | +1.48% |
| Week 4 | $0.77 | $0.9182 | $1.09 | +1.98% |
| Week 5 | $0.7579 | $0.9227 | $1.12 | +2.49% |
| Week 6 | $0.7474 | $0.9272 | $1.15 | +2.99% |
| Week 7 | $0.7382 | $0.9318 | $1.18 | +3.50% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
BioCardia, Inc. is a clinical-stage regenerative medicine company that develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company is based in Sunnyvale, California.
Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. BioCardia also develops CardiALLO, an allogeneic mesenchymal stem cell therapy in Phase II for ischemic heart failure; PulmALLO for acute respiratory distress syndrome; and an allogeneic cell therapy platform. The Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; Heart3D for fusion imaging; and morph DNA and avance steerable introducers are part of its portfolio.
It has a license and distribution agreement with Biomet Biologics, LLC.
BioCardia is based in Sunnyvale, California, and operates in the healthcare sector focusing on regenerative medicine therapies and delivery platforms for cardiovascular and pulmonary diseases.
BioCardia, Inc. (BCDA) currently trades at $0.955 per share and has a market capitalization of $10.86M. It is ranked 5128 by market cap among public companies.
The near-term price setup is detailed in the forecast, which shows a 2026 average price of $0.955 with a range from $0.90 to $1.37 and a Neutral sentiment. The 2027–2030 period retains Neutral sentiment with gradual upside in the average prices (2027 avg $1.08, 2028 avg $0.9914, 2029 avg $0.9751, 2030 avg $0.9833) and corresponding max values approaching $1.50.
From 2031 onward, the forecast shifts to a Bullish stance with rising averages and higher ROIs (2031 avg $1.15 with ROI 20.7; 2032 avg $1.29 with ROI 35.6; 2033 avg $1.32 with ROI 38.2; 2034 avg $1.39 with ROI 45.9; 2035 avg $1.27 with ROI 32.8). The longer-horizon outlook strengthens further, with 2040 avg $1.82 and ROI 90.3, and 2050 avg $3.45 with ROI 261.5.
A major floor 26.0% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 38.8% above — a clean break opens room to run.
A major ceiling 55.5% above — clearing it would confirm fresh momentum.
Key BCDA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BCDA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.92 | Sell | $0.9254 | Sell |
| MA 10 | $0.962 | Sell | $0.9612 | Sell |
| MA 20 | $1.04 | Sell | $1.02 | Sell |
| MA 50 | $1.13 | Sell | $1.10 | Sell |
| MA 100 | $1.20 | Sell | $1.20 | Sell |
| MA 200 | $1.35 | Sell | $1.44 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 32.81 | Neutral |
| Stoch RSI (14) | 40.94 | Neutral |
| CCI (20) | -109.25 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -18.92 | Sell |
| Bollinger %B (20,2) | 0.12 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.68 | Sell |
| Awesome (5,34) | -0.18 | Sell |
| Ultimate (7,14,28) | 31.60 | Neutral |
| Momentum (10) | -0.22 | Sell |
| Aroon Osc (25) | -96.00 | Sell |
| Hull MA (9) | 0.91 | Sell |
| ADX (14) | 24.02 | Sell |
| ATR (14) | 0.03 | Info |
The near-term technical picture is Bearish in sentiment. The RSI(14) is 40, indicating modest downside momentum. The 50-day simple moving average (SMA50) sits at $1.14 and the 200-day simple moving average (SMA200) sits at $1.36, suggesting the price is hovering below longer-term resistance.
Key support is at $0.90 and resistance at $1.25. The 30-day trading range spans from a low of $0.7643 to a high of $1.19, highlighting limited upside in the immediate term and potential for volatility given the 60% annualized volatility.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.90 | $0.9003 | $1.29 | 0% | Neutral | |
| $0.7847 | $1.01 | $1.39 | +12% | Neutral | |
| $0.7088 | $0.9445 | $1.35 | +5% | Neutral | |
| $0.6689 | $0.9172 | $1.36 | +2% | Neutral | |
| $0.6496 | $0.9137 | $1.39 | +1% | Neutral | |
| $0.7501 | $1.08 | $1.69 | +20% | Neutral | |
| $0.8184 | $1.20 | $1.92 | +34% | Bullish | |
| $0.8149 | $1.22 | $1.99 | +36% | Bullish | |
| $0.8533 | $1.31 | $2.17 | +45% | Bullish | |
| $0.7583 | $1.18 | $2.00 | +32% | Bullish | |
| $0.9966 | $1.70 | $3.07 | +89% | Bullish | |
| $1.59 | $3.17 | $6.33 | +252% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $0.90 | $0.9003 | $1.06 | +0.00% |
| June 2026 | $0.7945 | $0.9375 | $1.14 | +4.13% |
| July 2026 | $0.8051 | $0.9598 | $1.18 | +2.38% |
| August 2026 | $0.7814 | $0.9392 | $1.17 | -2.15% |
| September 2026 | $0.7871 | $0.9523 | $1.20 | +1.40% |
| October 2026 | $0.8242 | $1.00 | $1.28 | +5.36% |
| November 2026 | $0.8268 | $1.01 | $1.30 | +0.87% |
| December 2026 | $0.8106 | $0.9973 | $1.29 | -1.45% |
Click any year to see its month-by-month BCDA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, BCDA is projected to trade between $0.90 and $1.29, averaging $0.9003 — a potential gain of 0% from today's $0.9003. A consolidation phase looks the most probable path here.
BioCardia, Inc.'s 2027 outlook centres on $1.01, within a $0.7847 to $1.39 range. That is up +12% on the projected 2026 average. That marks a +12% change versus current levels. Price action looks broadly range-bound.
By 2028, BCDA could reach as high as $1.35, with a base case around $0.9445 and support toward $0.7088 — roughly +5% from $0.9003. A consolidation phase looks the most probable path here.
Expect BCDA to range from $0.6689 to $1.36 through 2029. The $0.9172 average target implies a +2% move from current prices. That is -3% versus the projected 2028 average. Price action looks broadly range-bound.
The BCDA price prediction for 2030 points to an average of $0.9137 (low $0.6496, high $1.39) — a potential gain of +1% on today's $0.9003. A consolidation phase looks the most probable path here.
In 2031, BCDA is projected to trade between $0.7501 and $1.69, averaging $1.08 — a potential gain of +20% from today's $0.9003. That is up +18% on the projected 2030 average. Price action looks broadly range-bound.
BioCardia, Inc.'s 2032 outlook centres on $1.20, within a $0.8184 to $1.92 range. That is up +12% on the projected 2031 average. That marks a +34% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, BCDA could reach as high as $1.99, with a base case around $1.22 and support toward $0.8149 — roughly +36% from $0.9003. Momentum favours further upside here.
Expect BCDA to range from $0.8533 to $2.17 through 2034. The $1.31 average target implies a +45% move from current prices. That is up +7% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The BCDA price prediction for 2035 points to an average of $1.18 (low $0.7583, high $2.00) — a potential gain of +32% on today's $0.9003. Momentum favours further upside here.
In 2040, BCDA is projected to trade between $0.9966 and $3.07, averaging $1.70 — a potential gain of +89% from today's $0.9003. That is up +43% on the projected 2035 average. Buyers look set to stay in control over this stretch.
BioCardia, Inc.'s 2050 outlook centres on $3.17, within a $1.59 to $6.33 range. That is up +86% on the projected 2040 average. That marks a +252% change versus current levels. Momentum favours further upside here.
Investing $1,000 in BCDA today (≈ 1,110.740864 BCDA) could be worth
$3,516.2
+$2,516.2 (+252%) by 2050 · US Dollar
Based on the average projected BCDA price of $3.17 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BCDAwould be worth at today's price.
$1,000 invested in BCDA on May 27, 2025 (≈ 483.091803 BCDA) would be worth
$434.93
-$565.07 (-56.5%) today · 0.43× · US Dollar
Based on a BCDA entry price of $2.07 vs. today's $0.9003.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.92 | $978.59 | -2.1% |
| 1 month ago | $1.16 | $776.12 | -22.4% |
| 3 months ago | $1.24 | $726.05 | -27.4% |
| 6 months ago | $1.45 | $620.9 | -37.9% |
| 1 year ago | $2.07 | $434.93 | -56.5% |
| All time (5.0y) ago | $62.4 | $14.43 | -98.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BCDA forecast.
Our base-case forecast reaches $1.80 around 2050.
Implied market cap at $1.80: $20.47M
The multi-year forecast shows a shift from Neutral to Bullish sentiment starting in 2031, with notable upside in the ensuing years. The 2031–2035 window features rising average prices and rising ROIs, culminating in 2034 with an average of $1.39 and ROI of 45.9%, then 2035 with an average of $1.27 and ROI of 32.8.
The longer horizon strengthens considerably: 2040’s average price is forecast at $1.82 with a 90.3% ROI, and 2050’s average price is forecast at $3.45 with a 261.5% ROI. These figures imply substantial upside potential if the projected path materializes, but they are not guarantees and depend on future market conditions and execution.
Overall, the outlook remains uncertain in the near term, with a clear transition to much stronger price momentum in the longer term. Investors should consider the wide potential price path and the associated risks when evaluating BCDA as a long-term holding.
Tap a question to reveal the answer.
The 2030 forecast shows a min of $0.6964, an average of $0.9833, and a max of $1.50, with a ROI of 3% and a Neutral sentiment.
Near term (2026–2030) is Neutral, with positive momentum beginning in 2031 (Bullish) and ROIs rising to 20.7% (2031), 35.6% (2032), up to 261.5% (2050). These are estimates and not guarantees.
Yes. The forecast shows max values around $2.07 (2032), $2.16 (2033), and $2.32 (2034), with even higher possible later (2050 max $6.95).
Current price is $0.955 and market cap is $10.86M.
The 30-day range is from $0.7643 to $1.19, with a 2026 average of $0.955, a 2026 min of $0.90, and a 2026 max of $1.37. The sentiment is Neutral and RSI is 40, indicating mixed near-term momentum.
BioCardia, Inc. Community Discussion
0Share your BioCardia, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.